pyrimethamine has been researched along with marimastat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Avery, VM; Butler, GS; Drinkwater, N; Duffy, S; Grin, PM; Kassiou, M; Lucantoni, L; Malcolm, TR; McGowan, S; Overall, CM; Scammells, PJ; Vinh, NB | 1 |
2 other study(ies) available for pyrimethamine and marimastat
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
Topics: Aminopeptidases; Antimalarials; Binding Sites; Catalytic Domain; Cell Survival; Drug Resistance; HEK293 Cells; Humans; Hydroxamic Acids; Molecular Docking Simulation; Plasmodium; Protease Inhibitors; Protozoan Proteins; Structure-Activity Relationship | 2019 |